Similar β2M deletions and HLA class I loss have been reported in NSCLC biopsies obtained after progression on anti-PD-1 therapy, correlating with reduced antigen presentation and poor clinical outcome (37). The gene discussed is B2M; the disease is non-small cell lung carcinoma.